- Home
- NRXS vs CASI Comparison
NRXS vs CASI Comparison
Compare NRXS & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXS
- CASI
- Stock Information
- Founded
- NRXS 2011
- CASI 1991
- Country
- NRXS United States
- CASI China
- Employees
- NRXS N/A
- CASI N/A
- Industry
- NRXS
- CASI Biotechnology: Pharmaceutical Preparations
- Sector
- NRXS
- CASI Health Care
- Exchange
- NRXS Nasdaq
- CASI Nasdaq
- Market Cap
- NRXS 25.8M
- CASI 24.9M
- IPO Year
- NRXS 2023
- CASI 1996
- Fundamental
- Price
- NRXS $2.99
- CASI $1.64
- Analyst Decision
- NRXS Strong Buy
- CASI Strong Buy
- Analyst Count
- NRXS 1
- CASI 1
- Target Price
- NRXS $7.00
- CASI $4.00
- AVG Volume (30 Days)
- NRXS 1.0M
- CASI 62.3K
- Earning Date
- NRXS 11-12-2025
- CASI 11-13-2025
- Dividend Yield
- NRXS N/A
- CASI N/A
- EPS Growth
- NRXS N/A
- CASI N/A
- EPS
- NRXS N/A
- CASI N/A
- Revenue
- NRXS $3,217,531.00
- CASI $31,564,000.00
- Revenue This Year
- NRXS $62.14
- CASI N/A
- Revenue Next Year
- NRXS $131.87
- CASI N/A
- P/E Ratio
- NRXS N/A
- CASI N/A
- Revenue Growth
- NRXS 41.93
- CASI 36.64
- 52 Week Low
- NRXS $1.33
- CASI $1.09
- 52 Week High
- NRXS $6.20
- CASI $6.44
- Technical
- Relative Strength Index (RSI)
- NRXS 45.67
- CASI 43.72
- Support Level
- NRXS $2.94
- CASI $1.56
- Resistance Level
- NRXS $3.96
- CASI $1.73
- Average True Range (ATR)
- NRXS 0.31
- CASI 0.14
- MACD
- NRXS -0.06
- CASI -0.02
- Stochastic Oscillator
- NRXS 12.61
- CASI 14.04
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.